FGFR2 and pancreatic neuroendocrine neoplasm: Nintedanib is a dual inhibitor of VEGFR1, -2, and -3 as well as FGFR2 and showed both antiangiogenic and antitumor activity in the RIP1-Tag2 transgenic mouse model of tumorigenesis for pancreatic NEN (44).